Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons

Abstract

Obesity is a growing global health concern. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, have emerged as potential treatments. GLP-1 receptor agonists regulate appetite and can promote weight loss. Some GLP-1 receptor agonists, though Food and Drug Administration (FDA)-approved for diabetes, are also used off-label for weight loss alone. Rapid weight and fat loss with these medications can lead to what has been called “Ozempic Face” on social media and in the lay press, where facial volume and fat are depleted, resulting in wrinkles and sagging skin. Prescribers rarely counsel patients about the potential impact on the face, and the plastic surgery community faces a challenge in managing the facial changes associated with rapid weight loss. Dermal fillers, skin tightening techniques, and surgical interventions are useful for both restoration of facial volume and to manage excess skin. Discontinuation of GLP-1 receptor agonists should be considered prior to general anesthesia due to delayed gastric emptying while on these medications. As the popularity of GLP-1 receptor agonists grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations.

Keywords

facial aging - weight loss - fat loss - semaglutide - Ozempic face

Disclaimer

This article is not intended to guide clinicians when using semaglutide for the treatment of type 2 diabetes or obesity. For this information, please refer to prescribing information at FDA.gov for specific medications.

Publication History

Accepted Manuscript online:
04 August 2023

Article published online:
29 August 2023

• References

• 1 Suran M. As Ozempic's popularity soars, here's what to know about semaglutide and weight loss. JAMA 2023; 329 (19) 1627-1629
• 2 Wilding JPH, Batterham RL, Calanna S. et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384 (11) 989-1002
• 3 Rubino D, Abrahamsson N, Davies M. et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021; 325 (14) 1414-1425
• 4 Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery. . ASA Suggests. Accessed July 07, 2023 at: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery
• 5 Couto RA, Waltzman JT, Tadisina KK. et al. Objective assessment of facial rejuvenation after massive weight loss. Aesthetic Plast Surg 2015; 39 (06) 847-855
• 6 Couto RA, Charafeddine AH, Zins JE. Facelift in patients with massive weight loss. Clin Plast Surg 2019; 46 (04) 559-571
• 7 Harris E. Oral semaglutide led to similar weight loss as injection, company says. JAMA 2023; 329 (23) 2011